Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →This systematic review of 11 observational studies encompassing 136 children found that isolated sphenoid sinus disease commonly presented with headache, sometimes with ocular or cranial nerve manifestations, and was frequently initially misdiagnosed, while tumors accounted for only five cases.
The evidence supports considering early CT or MRI when persistent or atypical pediatric headache is accompanied by ocular symptoms or cranial nerve deficits; it can only be inferred—not established—that reducing diagnostic delay could expedite treatment of rare sphenoid tumors and other lesions and limit neurological sequelae.
In a retrospective cohort of 289 higher-risk young adult childhood-cancer survivors transitioned through a protocolized care pathway, 49.5% had no documented adult survivorship-clinic visit within two years, with failure associated with fewer prior survivorship visits, lower education, and possibly psychiatric comorbidity.
The study provides associative evidence that transition failure identifies a substantial care-delivery gap; it is reasonable—but not tested here—to hypothesize that intensified pre-transition engagement and targeted navigation or psychiatric support, particularly for vulnerable subgroups, could improve continuity of survivorship care.
In a retrospective cohort of 112 pediatric patients with high-risk hematologic malignancies undergoing allogeneic HSCT, a higher graft CD3+/CD4−CD8− T-cell ratio was independently associated with greater day-100 grade II–IV acute graft-versus-host disease incidence.
The evidence supports the graft CD3+/CD4−CD8− T-cell ratio as a candidate aGVHD risk biomarker; it is an untested inference that prospectively selecting or modifying graft composition to lower this ratio would reduce aGVHD without compromising disease control or immune recovery.
In a retrospective volumetric MRI analysis of 60 surgically treated adamantinomatous craniopharyngiomas without planned adjuvant radiotherapy, greater extent of resection and lower residual solid volume were associated with longer progression-free survival, while residual cystic disease predicted progression.
The evidence supports postoperative tumor volumetry as a prognostic tool; it may, as an inference requiring prospective validation, help select patients for intensified surveillance or adjuvant radiotherapy rather than prescribing the same postoperative strategy to all patients.
In a single-center retrospective cohort of 58 children with DIPG, 22 received reirradiation at progression, which was associated with longer overall survival, while doses above 50 Gy and progression after more than 9 months were also associated with better survival.
The record provides observational evidence that reirradiation—particularly 50–54 Gy in selected patients—correlates with longer survival and was generally tolerated; it remains an unproven hypothesis that the higher dose itself improves survival because treatment selection, disease course, and other confounders were not controlled in the supplied abstract.
The study reports that the engineered anti-GD2/ROR1 bispecific IgG1 G/R-001 binds both targets and produces concentration-dependent in vitro cytotoxicity in neuroblastoma and ROR1-positive breast cancer cell lines, with the greatest killing observed in a dual-positive neuroblastoma line.
The reported binding and cytotoxicity support G/R-001 as a preclinical dual-antigen therapeutic candidate; it is reasonable—but not yet demonstrated—to hypothesize that simultaneous GD2/ROR1 targeting could increase killing of dual-positive neuroblastoma and reduce single-antigen escape, while the proposed NK-cell synergy requires direct validation.
This single-center retrospective pilot study describes seven culture-confirmed candidemia cases in a Jordanian pediatric oncology unit, including frequent Candida tropicalis and azole resistance, that temporally coincided with a water leak and prompted a multidisciplinary infection-control response.
The record shows that environmental remediation, infection-control measures, and adjusted antifungal prophylaxis were implemented during the cluster; it supports the hypothesis—but does not establish—that a criteria-driven bundle could reduce subsequent candidemia risk in resource-limited pediatric oncology units.
In a retrospective comparison of 200 children aged 0–6 years, 80 kVp chest CT with 80% ASiR-V reconstruction reduced estimated effective radiation dose by approximately 48% versus conventional 100 kVp CT while maintaining comparable subjective diagnostic image quality.
The study directly supports a dose-optimization strategy for pediatric chest imaging; it can be inferred, but is not demonstrated here, that reducing ionizing-radiation exposure could lower cumulative imaging-related toxicity and long-term cancer risk in children who require repeated CT, including pediatric oncology patients.
In a two-center retrospective cohort of 147 children with newly diagnosed Wilms tumor, hypertension occurred in 51%, was associated with several tumor-related features, and caused secondary complications in 8% of hypertensive patients, prompting multidisciplinary management recommendations.
The study provides observational evidence that routine blood-pressure screening can identify a frequent and sometimes complicated comorbidity at Wilms tumor diagnosis; it is reasonable but not proven to infer that risk-adapted monitoring and standardized antihypertensive management could reduce acute hypertension-related complications.
In a retrospective multicenter cohort of 112 children with core-binding factor AML, sequential fusion-transcript MRD thresholds—particularly at the end of consolidation—and KIT D816 status were associated with survival and relapse outcomes.
The evidence supports sequential MRD plus KIT status as a prognostic stratification approach; it may, by inference, help identify children who could benefit from treatment intensification, de-escalation, or closer surveillance, but the record does not test any MRD-guided or KIT-directed therapeutic strategy.
The paper summarizes randomized-trial meta-analysis and prospective-cohort evidence associating estrogen-only menopausal therapy after hysterectomy with lower breast cancer incidence in population-risk and BRCA-variant carriers, while emphasizing uncertainty and shared decision-making.
Evidence in the supplied record supports an association between estrogen-only menopausal therapy and reduced breast cancer incidence in selected adults without a uterus; it remains an inference—not an established preventive indication—that estradiol could be used to lower breast cancer risk, and the record provides no direct pediatric-oncology evidence.
Using accelerator and nozzle modeling, phantom analysis, and a sample pediatric central nervous system cancer plan, the study reports that smaller proton spot sizes—and, less strongly, narrower energy spreads—improved organ-at-risk sparing while maintaining comparable target coverage.
The supplied evidence supports a dosimetric planning hypothesis that a prospective dielectric wall accelerator configured for an approximately 1 mm lateral spot size and 0.05%–0.5% energy spread could reduce normal-tissue dose in pediatric proton therapy; any resulting reduction in toxicity or improvement in clinical outcomes remains an untested inference.
